Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review
Objectives Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients’ preferenc...
Saved in:
| Published in: | The patient : patient-centered outcomes research Vol. 10; no. 1; pp. 17 - 37 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Cham
Springer International Publishing
01.02.2017
Springer Nature B.V |
| Subjects: | |
| ISSN: | 1178-1653, 1178-1661 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Objectives
Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients’ preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment.
Methods
We searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options.
Results
Overall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls.
Conclusion
Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment. |
|---|---|
| AbstractList | Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients' preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment. We searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options. Overall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls. Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment. OBJECTIVESSince the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients' preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment.METHODSWe searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options.RESULTSOverall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls.CONCLUSIONStroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment. Objectives Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients’ preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment. Methods We searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options. Results Overall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls. Conclusion Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment. Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for stroke prevention in patients with atrial fibrillation (AF). For various reasons, it is important to consider patients' preferences regarding type of medication, particularly in view of the established relationship between preferences towards treatment, associated burden of treatment, and treatment adherence. This review aimed to systematically analyse the scientific literature assessing the preferences of AF patients with regard to long-term oral anticoagulant (OAC) treatment. We searched the MEDLINE, Scopus and EMBASE databases (from 1980 to 2015), added records from reference lists of publications found, and conducted a systematic review based on all identified publications. Outcomes of interest included any quantitative information regarding the opinions or preferences of AF patients towards OAC treatment, ideally specified according to different clinical or convenience attributes describing different OAC treatment options. Overall, 27 publications describing the results of studies conducted in 12 different countries were included in our review. Among these, 16 studies analysed patient preferences towards OACs in general. These studies predominantly assessed which benefits (mainly lower stroke risk) AF patients would require to tolerate harms (mainly higher bleeding risk) associated with an OAC. Most studies showed that patients were willing to accept higher bleeding risks if a certain threshold in stroke risk reduction could be reached. Nevertheless, most of the publications also showed that the preferences of AF patients towards OACs may differ from the perspective of clinical guidelines or the perspective of physicians. The remaining 11 studies included in our review assessed the preferences of AF patients towards specific OAC medication options, namely NOACs versus VKAs. Our review showed that AF patients prefer easy-to-administer treatments, such as treatments that are applied once daily without any food/drug interactions and without the need for bridging and frequent blood controls. Stroke risk reduction and a moderate increase in the risk of bleeding are the most important attributes for an AF patient when deciding whether they are for or against OAC treatment. If different anticoagulation options have similar clinical characteristics, convenience attributes matter to patients. In this review, AF patients favour attribute levels that describe NOAC treatment. |
| Author | Bauer, Sabine Kohlmann, Thomas Wilke, Thomas Mueller, Sabrina Bauersachs, Rupert |
| Author_xml | – sequence: 1 givenname: Thomas surname: Wilke fullname: Wilke, Thomas email: thomas.wilke@ipam-wismar.de organization: IPAM-Institut für Pharmakoökonomie und Arzneimittellogistik – sequence: 2 givenname: Sabine surname: Bauer fullname: Bauer, Sabine organization: Ingress-Health HWM GmbH – sequence: 3 givenname: Sabrina surname: Mueller fullname: Mueller, Sabrina organization: Ingress-Health HWM GmbH – sequence: 4 givenname: Thomas surname: Kohlmann fullname: Kohlmann, Thomas organization: Institute for Community Medicine, University Medicine Greifswald – sequence: 5 givenname: Rupert surname: Bauersachs fullname: Bauersachs, Rupert organization: Department of Vascular Medicine, Klinikum Darmstadt GmbH, Centre for Thrombosis and Hemostasis, University of Mainz |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27461276$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kV9rFDEUxYNU7B_9AL5IwBdfRpPMTDLjg7AUq8JCi9bnkMncbFN3kzXJVPbbe9dpSy3oQ5iE-7uHc-Yck4MQAxDykrO3nDH1LjdMKF4xLvF0bdU_IUecq67iUvKD-3tbH5LjnK8ZkziQz8ihUI3kQskj8uPCFA-h0IsEDhIEC5m6mOh5Mmu6CMXbaFbTGqkY6OUVJLPdUR_ooiSPxJkfkl_P4_d0Qb_tcoENPi1d-oJ0mRLQr3Dj4ddz8tSZdYYXt98T8v3s4-Xp52p5_unL6WJZ2baWpbK26QSrGzfYgY-NZLLp-25QdmCW92J01kjnHEhpRw6qace-HUcjJBjnlGjrE_Jh1t1OwwZGi_EwjN4mvzFpp6Px-u9J8Fd6FW90K1omlUCBN7cCKf6cIBe98dkCxgwQp6x5JxBDZzWirx-h13FKAeNp9Nq0XLWyR-rVQ0f3Vu56QEDNgE0xZ6xCW1_-_FQ06NeaM71vXM-Na2xc7xvXe2n-aPNO_H87Yt7JyIYVpAem_7n0GzC8v5M |
| CitedBy_id | crossref_primary_10_1007_s11239_018_1617_2 crossref_primary_10_36290_vnl_2017_125 crossref_primary_10_1093_eurjcn_zvae177 crossref_primary_10_1007_s11239_021_02450_2 crossref_primary_10_1007_s40271_022_00587_7 crossref_primary_10_3389_fcvm_2019_00017 crossref_primary_10_1016_j_cjco_2025_02_014 crossref_primary_10_1016_j_jtha_2024_12_029 crossref_primary_10_1016_j_hlc_2019_11_012 crossref_primary_10_1186_s43094_024_00595_4 crossref_primary_10_1182_bloodadvances_2021004267 crossref_primary_10_2147_PPA_S236964 crossref_primary_10_3390_jcm8020215 crossref_primary_10_3390_life15081298 crossref_primary_10_1186_s12875_016_0574_0 crossref_primary_10_1136_bmjopen_2020_042518 crossref_primary_10_1161_CIRCULATIONAHA_119_043318 crossref_primary_10_1016_j_ahj_2020_06_014 crossref_primary_10_1055_s_0041_1736242 crossref_primary_10_47102_annals_acadmedsg_2022437 crossref_primary_10_7759_cureus_35220 crossref_primary_10_7759_cureus_62606 crossref_primary_10_3390_pharmacy11050153 crossref_primary_10_1002_clc_22971 crossref_primary_10_1016_j_jacc_2020_12_053 crossref_primary_10_1080_14779072_2023_2275662 crossref_primary_10_1111_ejh_13171 crossref_primary_10_1136_bmjopen_2017_018242 crossref_primary_10_1371_journal_pmed_1003730 crossref_primary_10_1016_j_urolonc_2020_05_030 crossref_primary_10_1055_s_0042_1750385 crossref_primary_10_1111_bcpt_12762 crossref_primary_10_1111_jce_16029 crossref_primary_10_1161_STROKEAHA_122_038752 crossref_primary_10_15829_1560_4071_2021_4402 crossref_primary_10_3389_fcvm_2021_675969 crossref_primary_10_1007_s40256_021_00482_w crossref_primary_10_1093_eurjcn_zvae116 crossref_primary_10_14309_ajg_0000000000001627 crossref_primary_10_1093_jcag_gwac010 crossref_primary_10_1007_s40256_018_0293_0 crossref_primary_10_1016_j_ihj_2019_04_001 crossref_primary_10_1097_FJC_0000000000000936 crossref_primary_10_1161_JAHA_118_011205 crossref_primary_10_1186_s12874_017_0448_8 crossref_primary_10_1017_S1463423620000171 crossref_primary_10_1111_imj_15136 crossref_primary_10_1007_s00228_017_2307_2 crossref_primary_10_4330_wjc_v14_i11_576 crossref_primary_10_1007_s40271_018_0329_1 crossref_primary_10_2217_cer_2020_0001 crossref_primary_10_1111_bcpt_13145 crossref_primary_10_1080_14656566_2018_1511703 crossref_primary_10_1016_j_thromres_2022_03_011 crossref_primary_10_1016_j_jacc_2019_01_017 crossref_primary_10_1093_europace_euae291 crossref_primary_10_1002_jhm_13464 crossref_primary_10_1007_s11239_020_02194_5 crossref_primary_10_1177_17539447221093963 crossref_primary_10_1002_clc_70038 crossref_primary_10_1007_s40271_020_00420_z crossref_primary_10_1016_j_thromres_2021_10_025 crossref_primary_10_1161_JAHA_119_012023 crossref_primary_10_3390_healthcare8040404 crossref_primary_10_1007_s15006_019_0920_y crossref_primary_10_1093_eurheartj_suab152 crossref_primary_10_1016_j_giec_2021_12_006 crossref_primary_10_1016_j_jstrokecerebrovasdis_2022_106894 crossref_primary_10_1186_s12955_020_01471_4 crossref_primary_10_1111_bcp_13739 crossref_primary_10_1186_s13643_022_02098_w crossref_primary_10_1007_s11910_017_0774_6 crossref_primary_10_1055_a_1789_4824 crossref_primary_10_1177_1060028019889414 crossref_primary_10_1016_j_ijcard_2019_06_014 crossref_primary_10_1093_eurjcn_zvad094 |
| Cites_doi | 10.1160/TH11-11-0768 10.1093/europace/eus087 10.1007/s40520-014-0243-x 10.1378/chest.11-2290 10.1177/0272989X05280558 10.1007/s11239-014-1136-8 10.1016/j.jval.2013.03.069 10.1185/03007995.2012.677419 10.1056/NEJMoa1009638 10.1136/bmj.g3655 10.1093/europace/eus333 10.1258/1355819011927288 10.1001/archinte.1996.00440150095011 10.1177/0272989X9601600311 10.1177/2042098614552073 10.1097/MJT.0b013e3182373591 10.1007/s11739-014-1155-7 10.1007/s11239-015-1191-9 10.1093/eurheartj/ehn599 10.1056/NEJMoa0905561 10.1007/s11739-012-0844-3 10.1016/j.jval.2013.03.1514 10.1007/s40273-014-0170-x 10.1161/CIRCOUTCOMES.114.001013 10.1056/NEJMoa1107039 10.1136/ewjm.174.5.311 10.1371/journal.pmed.1000097 10.1001/jama.285.22.2864 10.1016/S0735-1097(00)01107-4 10.1016/S0002-9149(99)00713-4 10.1093/eurheartj/ehq278 10.1185/030079905X50624 10.1378/chest.09-1584 10.1136/bmj.323.7323.1218 10.1016/S1098-3015(10)74667-2 10.1016/j.cjca.2015.09.023 10.1161/CIR.0b013e318214876d 10.1093/eurheartj/ehm358 10.1007/s40273-014-0188-0 10.1186/1471-2261-13-108 10.1007/s11239-015-1263-x 10.1016/j.ijcard.2008.10.045 10.1111/hex.12201 10.1016/j.jval.2015.03.064 10.1160/TH13-05-0424 10.1016/j.jacc.2007.09.065 10.1136/bmj.320.7246.1380 10.1016/S0002-9343(02)01236-6 10.1016/j.vhri.2015.03.016 10.33588/rn.5501.2011580 10.1016/j.jval.2012.08.2223 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2016 Copyright Springer Science & Business Media Feb 2017 |
| Copyright_xml | – notice: The Author(s) 2016 – notice: Copyright Springer Science & Business Media Feb 2017 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 4T- 7RV 7X7 7XB 88E 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU FYUFA GHDGH K9- K9. KB0 M0R M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7U8 7X8 C1K JXQ 5PM |
| DOI | 10.1007/s40271-016-0185-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Docstoc ProQuest Nursing & Allied Health Database Proquest Health and Medical Complete ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Consumer Health Database Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management Toxline PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Docstoc ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) TOXLINE MEDLINE - Academic Environmental Sciences and Pollution Management |
| DatabaseTitleList | ProQuest One Academic Middle East (New) TOXLINE MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: ProQuest Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1178-1661 |
| EndPage | 37 |
| ExternalDocumentID | PMC5250672 27461276 10_1007_s40271_016_0185_9 |
| Genre | Systematic Review Journal Article |
| GrantInformation_xml | – fundername: Bayer Pharma AG – fundername: ; |
| GroupedDBID | --- -EM 04C 0R~ 29O 3V. 4.4 406 53G 7RV 7X7 88E 8C1 8FI 8FJ 8R4 8R5 8UJ 95. AACDK AADNT AAIKX AAJKR AAKAS AASML AATNV ABAKF ABDZT ABFTV ABIVO ABJOX ABKCH ABKTR ABLLE ABPLI ABTKH ABTMW ABUWG ABXPI ACAOD ACCOQ ACDTI ACGFS ACMLO ACPIV ACZOJ ADBBV ADFZG ADURQ ADZCM ADZKW AEFQL AEJHL AEJRE AEMSY AEOHA AESKC AFKRA AFZKB AGDGC AGQEE AGQMX AHMBA AHSBF AIGIU AILAN ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW ASPBG AUKKA AVWKF AWSVR AXYYD AZQEC BENPR BGNMA BKEYQ BKNYI BMSDO BPHCQ BVXVI BYPQX C6C CAG CCPQU COF DCUDU DPUIP EBS EIHBH EJD EMOBN EX3 F5P FIGPU FLLZZ FNLPD FSGXE FYUFA HMCUK IAO IEA IHR ITC IWAJR J-C JZLTJ K9- LLZTM M0R M1P M4Y NAPCQ NQJWS NU0 O9- OAC OVD PQQKQ PROAC PSQYO Q2X ROL RSV SISQX SJYHP SNPRN SOHCF SOJ SPKJE SRMVM SSLCW SV3 TEORI TSG U9L UG4 UKHRP UTJUX VDBLX VFIZW W48 WOW ~JE AAYXX ABBRH ABDBE ABRTQ AFDZB AFFHD ATHPR AYFIA CITATION EBLON PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 4T- 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7U8 7X8 C1K JXQ PUEGO 5PM |
| ID | FETCH-LOGICAL-c536t-cc482034fbcb1d46064998b7cb0c192dfca6fffe66cd1e745d95dda26eaff7253 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 86 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000392646500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1178-1653 |
| IngestDate | Tue Nov 04 01:44:58 EST 2025 Wed Oct 01 14:47:27 EDT 2025 Fri Nov 07 23:32:41 EST 2025 Mon Jul 21 05:55:22 EDT 2025 Tue Nov 18 22:37:33 EST 2025 Sat Nov 29 07:53:34 EST 2025 Fri Feb 21 02:30:22 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Stroke Risk Rivaroxaban Bleeding Risk Atrial Fibrillation Apixaban |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c536t-cc482034fbcb1d46064998b7cb0c192dfca6fffe66cd1e745d95dda26eaff7253 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Literature Review-2 ObjectType-Feature-3 ObjectType-Article-2 content type line 23 ObjectType-Review-1 ObjectType-Undefined-4 |
| OpenAccessLink | https://link.springer.com/10.1007/s40271-016-0185-9 |
| PMID | 27461276 |
| PQID | 1924517569 |
| PQPubID | 38894 |
| PageCount | 21 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5250672 proquest_miscellaneous_1826724603 proquest_journals_1924517569 pubmed_primary_27461276 crossref_citationtrail_10_1007_s40271_016_0185_9 crossref_primary_10_1007_s40271_016_0185_9 springer_journals_10_1007_s40271_016_0185_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-02-01 |
| PublicationDateYYYYMMDD | 2017-02-01 |
| PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: New Zealand – name: Auckland |
| PublicationTitle | The patient : patient-centered outcomes research |
| PublicationTitleAbbrev | Patient |
| PublicationTitleAlternate | Patient |
| PublicationYear | 2017 |
| Publisher | Springer International Publishing Springer Nature B.V |
| Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
| References | Najafzadeh, Gagne, Choudhry, Polinski, Avorn, Schneeweiss (CR26) 2014; 7 Protheroe, Fahey, Montgomery, Peters (CR29) 2001; 174 Wilke, Groth, Mueller, Pfannkuche, Verheyen, Linder (CR50) 2012; 107 Barcellona, Luzza, Battino, Fenu, Marongiu (CR40) 2015; 10 Devereaux, Anderson, Gardner, Putnam, Flowerdew, Brownell (CR27) 2001; 323 Lip, Nieuwlaat, Pisters, Lane, Crijns (CR13) 2010; 137 Najafzadeh, Gagne, Choudhry, Polinski, Avorn, Schneeweiss (CR33) 2015; 18 Fang, Go, Chang, Borowsky, Pomernacki, Singer (CR4) 2008; 51 Jones, Pollit, Fitzmaurice, Cowan (CR21) 2014; 348 Levitan, Yuan, González, Hauber, Lees, Piccini (CR32) 2013; 16 Okumura, Inoue, Yasaka, Gonzalez, Hauber, Iwamoto (CR35) 2012; 15 Moher, Liberati, Tetzlaff, Altman (CR23) 2009; 6 Llewellyn-Thomas, Williams, Levy, Naylor (CR55) 1996; 16 Robinson, Thomson, Parkin, Sudlow, Eccles (CR37) 2001; 6 Davis, Hobbs, Kenkre, Roalfe, Iles, Lip (CR6) 2012; 14 Wilke, Groth, Mueller, Pfannkuche, Verheyen, Linder (CR5) 2013; 15 Kirchhof, Auricchio, Bax, Crijns, Camm, Diener (CR8) 2007; 28 Camm, Kirchhof, Lip, Schotten, Savelieva, Ernst (CR7) 2010; 31 Connolly, Ezekowitz, Yusuf, Eikelboom, Oldgren, Parekh (CR14) 2009; 361 Palacio, Kirolos, Tamariz (CR31) 2015; 9 CR43 Böttger, Thate-Waschke, Bauersachs, Kohlmann, Wilke (CR41) 2015; 40 Coleman, Roberts, Sobieraj, Lee, Alam, Kaur (CR54) 2012; 28 Attaya, Bornstein, Ronquillo, Volgman, Braun, Trohman (CR47) 2012; 19 Okumura, Inoue, Yasaka, Gonzalez, Hauber, Levitan (CR34) 2015; 6 Fumagalli, Cardini, Roberts, Boni, Gabbai, Calvani (CR17) 2015; 27 Boom, Berghuis, Nieuwkerk, Pinedo, Ba Ller (CR45) 2015; 73 Moia, Mantovani, Carpenedo, Scalone, Monzini, Cesana (CR56) 2013; 8 Friberg, Hammar, Rosenqvist (CR10) 2010; 31 Granger, Alexander, McMurray, Lopes, Hylek, Hanna (CR16) 2011; 365 Ryder, Benjamin (CR1) 1999; 84 Wang, Kong, Ko (CR48) 2013; 16 Alonso-Coello, Montori, Díaz, Devereaux, Mas, Diez (CR24) 2014; 18 CR58 Cottrell, LeReun, Tilden, Robinson (CR46) 2009; 12 Ghijben, Lancsar, Zavarsek (CR18) 2014; 32 Chugh, Blackshear, Shen, Hammill, Gersh (CR2) 2001; 37 Wilke, Groth, Pfannkuche, Harks, Fuchs, Maywald (CR51) 2015; 40 González-Rojas, Gimenez, Fernandez, Heineger, Martinez, Villar (CR30) 2012; 55 Fuster, Rydén, Cannom, Crijns, Curtis, Ellenbogen (CR11) 2011; 123 Bakhai, Sandberg, Mittendorf, Greiner, Oberdiek, Berto (CR19) 2013; 13 Casais, Meschengieser, Sanchez-Luceros, Lazzari (CR38) 2005; 21 Clark, Determann, Petrou, Moro, de Bekker-Grob (CR57) 2014; 32 Man-Son-Hing, Gage, Montgomery, Howitt, Thomson, Devereaux (CR53) 2005; 25 Sudlow, Thomson, Kenny, Rodgers (CR25) 1998; 48 MacLean, Mulla, Akl, Jankowski, Vandvik, Ebrahim (CR52) 2012; 141 Andrade, Krahn, Skanes, Purdham, Ciaccia, Connors (CR42) 2016; 32 CR22 CR20 Gebler-Hughes, Kemp, Bond (CR44) 2014; 5 Man-Son-Hing, Laupacis, O’Connor, Wells, Lemelin, Wood (CR28) 1996; 156 Stewart, Hart, Hole, McMurray (CR9) 2002; 113 Gage, Waterman, Shannon, Boechler, Rich, Radford (CR12) 2001; 285 Chien, Su, Hsu, Chang, Chen, Chen (CR3) 2010; 139 Patel, Mahaffey, Garg, Pan, Singer, Hacke (CR15) 2011; 365 Protheroe, Fahey, Montgomery, Peters (CR36) 2000; 320 Lahaye, Regpala, Lacombe, Sharma, Gibbens, Ball (CR39) 2014; 111 Wang, Xie, Kong, Lee, Ng, Ko (CR49) 2015; 40 HA Llewellyn-Thomas (185_CR55) 1996; 16 SJ Connolly (185_CR14) 2009; 361 S Stewart (185_CR9) 2002; 113 S Fumagalli (185_CR17) 2015; 27 S Lahaye (185_CR39) 2014; 111 M Man-Son-Hing (185_CR28) 1996; 156 Y Wang (185_CR48) 2013; 16 GYH Lip (185_CR13) 2010; 137 JG Andrade (185_CR42) 2016; 32 185_CR43 M Sudlow (185_CR25) 1998; 48 M Najafzadeh (185_CR33) 2015; 18 S Attaya (185_CR47) 2012; 19 D Moher (185_CR23) 2009; 6 Y Wang (185_CR49) 2015; 40 A Bakhai (185_CR19) 2013; 13 AM Palacio (185_CR31) 2015; 9 V Fuster (185_CR11) 2011; 123 S MacLean (185_CR52) 2012; 141 B Levitan (185_CR32) 2013; 16 J Protheroe (185_CR36) 2000; 320 D Barcellona (185_CR40) 2015; 10 PJ Devereaux (185_CR27) 2001; 323 P Ghijben (185_CR18) 2014; 32 BF Gage (185_CR12) 2001; 285 P Kirchhof (185_CR8) 2007; 28 ES Gebler-Hughes (185_CR44) 2014; 5 M Najafzadeh (185_CR26) 2014; 7 SS Chugh (185_CR2) 2001; 37 M Man-Son-Hing (185_CR53) 2005; 25 K Okumura (185_CR34) 2015; 6 P Alonso-Coello (185_CR24) 2014; 18 185_CR58 K Chien (185_CR3) 2010; 139 J Protheroe (185_CR29) 2001; 174 N González-Rojas (185_CR30) 2012; 55 CI Coleman (185_CR54) 2012; 28 MS Boom (185_CR45) 2015; 73 B Böttger (185_CR41) 2015; 40 MC Fang (185_CR4) 2008; 51 T Wilke (185_CR5) 2013; 15 M Moia (185_CR56) 2013; 8 L Friberg (185_CR10) 2010; 31 185_CR20 185_CR22 P Casais (185_CR38) 2005; 21 MD Clark (185_CR57) 2014; 32 K Okumura (185_CR35) 2012; 15 CB Granger (185_CR16) 2011; 365 MR Patel (185_CR15) 2011; 365 C Jones (185_CR21) 2014; 348 RC Davis (185_CR6) 2012; 14 T Wilke (185_CR51) 2015; 40 A Robinson (185_CR37) 2001; 6 S Cottrell (185_CR46) 2009; 12 T Wilke (185_CR50) 2012; 107 KM Ryder (185_CR1) 1999; 84 AJ Camm (185_CR7) 2010; 31 |
| References_xml | – ident: CR22 – volume: 107 start-page: 1053 year: 2012 end-page: 1065 ident: CR50 article-title: Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients publication-title: Thromb Haemost doi: 10.1160/TH11-11-0768 – volume: 14 start-page: 1553 year: 2012 end-page: 1559 ident: CR6 article-title: Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study publication-title: Europace doi: 10.1093/europace/eus087 – volume: 27 start-page: 99 year: 2015 end-page: 102 ident: CR17 article-title: Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report publication-title: Aging Clin Exp Res doi: 10.1007/s40520-014-0243-x – volume: 141 start-page: e1S year: 2012 end-page: e23S ident: CR52 article-title: Patient values and preferences in decision making for antithrombotic therapy: a systematic review. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines publication-title: Chest doi: 10.1378/chest.11-2290 – volume: 25 start-page: 548 year: 2005 end-page: 559 ident: CR53 article-title: Preference-based antithrombotic therapy in atrial fibrillation: implications for clinical decision making publication-title: Med Decis Mak doi: 10.1177/0272989X05280558 – volume: 40 start-page: 97 year: 2015 end-page: 107 ident: CR51 article-title: Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-014-1136-8 – volume: 73 start-page: 368 year: 2015 end-page: 372 ident: CR45 article-title: When do patients prefer a direct oral anticoagulant over a vitamin K antagonist? publication-title: Neth J Med – volume: 16 start-page: A11 year: 2013 ident: CR32 article-title: Patient and physician preferences in the United States for benefits and risks of anticoagulant use in atrial fibrillation: results from a conjoint-analysis study publication-title: Value Health doi: 10.1016/j.jval.2013.03.069 – volume: 28 start-page: 669 year: 2012 end-page: 680 ident: CR54 article-title: Effect of dosing frequency on chronic cardiovascular disease medication adherence publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.677419 – volume: 365 start-page: 883 year: 2011 end-page: 891 ident: CR15 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 348 start-page: g3655 year: 2014 ident: CR21 article-title: The management of atrial fibrillation: summary of updated NICE guidance publication-title: BMJ doi: 10.1136/bmj.g3655 – ident: CR58 – volume: 15 start-page: 486 year: 2013 end-page: 493 ident: CR5 article-title: Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients publication-title: Europace doi: 10.1093/europace/eus333 – volume: 6 start-page: 92 year: 2001 end-page: 98 ident: CR37 article-title: How patients with atrial fibrillation value different health outcomes: a standard gamble study publication-title: J Health Serv Res Policy doi: 10.1258/1355819011927288 – volume: 156 start-page: 1841 year: 1996 end-page: 1848 ident: CR28 article-title: Warfarin for atrial fibrillation. The patient’s perspective publication-title: Arch Intern Med doi: 10.1001/archinte.1996.00440150095011 – volume: 16 start-page: 262 year: 1996 end-page: 282 ident: CR55 article-title: Using a trade-off technique to assess patients’ treatment preferences for benign prostatic hyperplasia publication-title: Med Decis Mak doi: 10.1177/0272989X9601600311 – volume: 5 start-page: 220 year: 2014 end-page: 228 ident: CR44 article-title: Patients’ perspectives regarding long-term warfarin therapy and the potential transition to new oral anticoagulant therapy publication-title: Ther Adv Drug Saf doi: 10.1177/2042098614552073 – volume: 19 start-page: 432 year: 2012 end-page: 435 ident: CR47 article-title: Study of warfarin patients investigating attitudes toward therapy change (SWITCH Survey) publication-title: Am J Ther doi: 10.1097/MJT.0b013e3182373591 – volume: 10 start-page: 157 year: 2015 end-page: 163 ident: CR40 article-title: The criteria of the Italian Federation of Thrombosis Centres on DOACs: a “real world” application in nonvalvular atrial fibrillation patients already on vitamin K antagonist publication-title: Intern Emerg Med doi: 10.1007/s11739-014-1155-7 – volume: 40 start-page: 268 year: 2015 end-page: 273 ident: CR49 article-title: Patient-reported health preferences of anticoagulant-related outcomes publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-015-1191-9 – volume: 31 start-page: 967 year: 2010 end-page: 975 ident: CR10 article-title: Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehn599 – volume: 361 start-page: 1139 year: 2009 end-page: 1151 ident: CR14 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 8 start-page: 237 year: 2013 end-page: 243 ident: CR56 article-title: Patient preferences and willingness to pay for different options of anticoagulant therapy publication-title: Intern Emerg Med doi: 10.1007/s11739-012-0844-3 – volume: 16 start-page: A292 year: 2013 ident: CR48 article-title: Utility evaluation of health states related to stroke and stroke prophylaxis publication-title: Value Health doi: 10.1016/j.jval.2013.03.1514 – volume: 32 start-page: 883 year: 2014 end-page: 902 ident: CR57 article-title: Discrete choice experiments in health economics: a review of the literature publication-title: Pharmacoeconomics doi: 10.1007/s40273-014-0170-x – volume: 7 start-page: 912 year: 2014 end-page: 919 ident: CR26 article-title: Patients’ preferences in anticoagulant therapy: discrete choice experiment publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.114.001013 – volume: 9 start-page: 133 year: 2015 end-page: 138 ident: CR31 article-title: Patient values and preferences when choosing anticoagulants publication-title: Patient Prefer Adherence – volume: 365 start-page: 981 year: 2011 end-page: 992 ident: CR16 article-title: Apixaban versus warfarin in patients with atrial fibrillation publication-title: N Engl J Med doi: 10.1056/NEJMoa1107039 – ident: CR43 – volume: 174 start-page: 311 year: 2001 end-page: 315 ident: CR29 article-title: Effects of patients’ preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis publication-title: West J Med doi: 10.1136/ewjm.174.5.311 – volume: 6 start-page: e1000097 issue: 7 year: 2009 ident: CR23 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 285 start-page: 2864 year: 2001 end-page: 2870 ident: CR12 article-title: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation publication-title: JAMA doi: 10.1001/jama.285.22.2864 – volume: 37 start-page: 371 year: 2001 end-page: 378 ident: CR2 article-title: Epidemiology and natural history of atrial fibrillation: clinical implications publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(00)01107-4 – volume: 84 start-page: R131 year: 1999 end-page: R138 ident: CR1 article-title: Epidemiology and significance of atrial fibrillation publication-title: Am J Cardiol doi: 10.1016/S0002-9149(99)00713-4 – volume: 55 start-page: 11 year: 2012 end-page: 19 ident: CR30 article-title: Preferences for oral anticoagulant treatment in the medium and long term prevention of stroke in non valvular atrial fibrillation [in Spanish] publication-title: Rev Neurol – volume: 31 start-page: 2369 year: 2010 end-page: 2429 ident: CR7 article-title: Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq278 – volume: 21 start-page: 1085 year: 2005 end-page: 1090 ident: CR38 article-title: Patients’ perceptions regarding oral anticoagulation therapy and its effect on quality of life publication-title: Curr Med Res Opin doi: 10.1185/030079905X50624 – volume: 137 start-page: 263 year: 2010 end-page: 272 ident: CR13 article-title: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation publication-title: Chest doi: 10.1378/chest.09-1584 – volume: 323 start-page: 1218 year: 2001 end-page: 1222 ident: CR27 article-title: Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study publication-title: BMJ doi: 10.1136/bmj.323.7323.1218 – volume: 12 start-page: A339 year: 2009 ident: CR46 article-title: Preference and willingness to pay study to assess the value of an anticoagulation therapy modelled on dabigatran etexilate using discrete choice analysis: a UK pilot study of warfarin-naive atrial fibrillation patients publication-title: Value Health doi: 10.1016/S1098-3015(10)74667-2 – volume: 32 start-page: 747 year: 2016 end-page: 753 ident: CR42 article-title: Values and preferences of physicians and patients with nonvalvular atrial fibrillation who receive oral anticoagulation therapy for stroke prevention publication-title: Can J Cardiol doi: 10.1016/j.cjca.2015.09.023 – volume: 123 start-page: e269 year: 2011 end-page: e367 ident: CR11 article-title: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines publication-title: Circulation doi: 10.1161/CIR.0b013e318214876d – volume: 48 start-page: 1775 year: 1998 end-page: 1778 ident: CR25 article-title: A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences publication-title: Br J Gen Pract – volume: 15 start-page: A380 issue: 7 year: 2012 ident: CR35 article-title: Japanese patients and physicians preferences for anticoagulants use in atrial fibrillation: results from a conjoint-analysis study publication-title: Value Health – volume: 28 start-page: 2803 year: 2007 end-page: 2817 ident: CR8 article-title: Outcome parameters for trials in atrial fibrillation: executive summary publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm358 – volume: 32 start-page: 1115 year: 2014 end-page: 1127 ident: CR18 article-title: Preferences for oral anticoagulants in atrial fibrillation: a best-best discrete choice experiment publication-title: Pharmacoeconomics doi: 10.1007/s40273-014-0188-0 – volume: 13 start-page: 108 year: 2013 ident: CR19 article-title: Patient perspective on the management of atrial fibrillation in five European countries publication-title: BMC Cardiovasc Disord doi: 10.1186/1471-2261-13-108 – volume: 40 start-page: 406 year: 2015 end-page: 415 ident: CR41 article-title: Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-015-1263-x – volume: 139 start-page: 173 year: 2010 end-page: 180 ident: CR3 article-title: Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2008.10.045 – volume: 18 start-page: 2318 issue: 6 year: 2014 end-page: 2327 ident: CR24 article-title: Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives publication-title: Health Expect doi: 10.1111/hex.12201 – volume: 18 start-page: A9 year: 2015 end-page: A10 ident: CR33 article-title: Patient versus general population preferences in anticoagulant therapy publication-title: Value Health doi: 10.1016/j.jval.2015.03.064 – volume: 111 start-page: 465 year: 2014 end-page: 473 ident: CR39 article-title: Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation publication-title: Thromb Haemost doi: 10.1160/TH13-05-0424 – volume: 51 start-page: 810 year: 2008 end-page: 815 ident: CR4 article-title: Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.09.065 – volume: 320 start-page: 1380 year: 2000 end-page: 1384 ident: CR36 article-title: The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis publication-title: BMJ doi: 10.1136/bmj.320.7246.1380 – volume: 113 start-page: 359 year: 2002 end-page: 364 ident: CR9 article-title: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study publication-title: Am J Med doi: 10.1016/S0002-9343(02)01236-6 – ident: CR20 – volume: 6 start-page: 65 year: 2015 end-page: 72 ident: CR34 article-title: Comparing patient and physician risk tolerance for bleeding events associated with anticoagulants in atrial fibrillation: evidence from the United States and Japan publication-title: Value Health Reg Issues doi: 10.1016/j.vhri.2015.03.016 – volume: 174 start-page: 311 year: 2001 ident: 185_CR29 publication-title: West J Med doi: 10.1136/ewjm.174.5.311 – volume: 19 start-page: 432 year: 2012 ident: 185_CR47 publication-title: Am J Ther doi: 10.1097/MJT.0b013e3182373591 – volume: 32 start-page: 883 year: 2014 ident: 185_CR57 publication-title: Pharmacoeconomics doi: 10.1007/s40273-014-0170-x – volume: 113 start-page: 359 year: 2002 ident: 185_CR9 publication-title: Am J Med doi: 10.1016/S0002-9343(02)01236-6 – volume: 48 start-page: 1775 year: 1998 ident: 185_CR25 publication-title: Br J Gen Pract – volume: 40 start-page: 97 year: 2015 ident: 185_CR51 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-014-1136-8 – volume: 156 start-page: 1841 year: 1996 ident: 185_CR28 publication-title: Arch Intern Med doi: 10.1001/archinte.1996.00440150095011 – volume: 6 start-page: 65 year: 2015 ident: 185_CR34 publication-title: Value Health Reg Issues doi: 10.1016/j.vhri.2015.03.016 – volume: 15 start-page: A380 issue: 7 year: 2012 ident: 185_CR35 publication-title: Value Health – ident: 185_CR43 – volume: 51 start-page: 810 year: 2008 ident: 185_CR4 publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2007.09.065 – volume: 139 start-page: 173 year: 2010 ident: 185_CR3 publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2008.10.045 – volume: 32 start-page: 1115 year: 2014 ident: 185_CR18 publication-title: Pharmacoeconomics doi: 10.1007/s40273-014-0188-0 – volume: 9 start-page: 133 year: 2015 ident: 185_CR31 publication-title: Patient Prefer Adherence – volume: 7 start-page: 912 year: 2014 ident: 185_CR26 publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.114.001013 – volume: 10 start-page: 157 year: 2015 ident: 185_CR40 publication-title: Intern Emerg Med doi: 10.1007/s11739-014-1155-7 – volume: 31 start-page: 967 year: 2010 ident: 185_CR10 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehn599 – volume: 5 start-page: 220 year: 2014 ident: 185_CR44 publication-title: Ther Adv Drug Saf doi: 10.1177/2042098614552073 – ident: 185_CR20 – volume: 16 start-page: A292 year: 2013 ident: 185_CR48 publication-title: Value Health doi: 10.1016/j.jval.2013.03.1514 – volume: 73 start-page: 368 year: 2015 ident: 185_CR45 publication-title: Neth J Med – volume: 18 start-page: 2318 issue: 6 year: 2014 ident: 185_CR24 publication-title: Health Expect doi: 10.1111/hex.12201 – volume: 55 start-page: 11 year: 2012 ident: 185_CR30 publication-title: Rev Neurol doi: 10.33588/rn.5501.2011580 – volume: 14 start-page: 1553 year: 2012 ident: 185_CR6 publication-title: Europace doi: 10.1093/europace/eus087 – volume: 107 start-page: 1053 year: 2012 ident: 185_CR50 publication-title: Thromb Haemost doi: 10.1160/TH11-11-0768 – volume: 15 start-page: 486 year: 2013 ident: 185_CR5 publication-title: Europace doi: 10.1093/europace/eus333 – volume: 285 start-page: 2864 year: 2001 ident: 185_CR12 publication-title: JAMA doi: 10.1001/jama.285.22.2864 – volume: 6 start-page: 92 year: 2001 ident: 185_CR37 publication-title: J Health Serv Res Policy doi: 10.1258/1355819011927288 – volume: 6 start-page: e1000097 issue: 7 year: 2009 ident: 185_CR23 publication-title: PLoS Med doi: 10.1371/journal.pmed.1000097 – volume: 365 start-page: 981 year: 2011 ident: 185_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa1107039 – ident: 185_CR58 doi: 10.1016/j.jval.2012.08.2223 – volume: 123 start-page: e269 year: 2011 ident: 185_CR11 publication-title: Circulation doi: 10.1161/CIR.0b013e318214876d – volume: 31 start-page: 2369 year: 2010 ident: 185_CR7 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehq278 – volume: 84 start-page: R131 year: 1999 ident: 185_CR1 publication-title: Am J Cardiol doi: 10.1016/S0002-9149(99)00713-4 – volume: 323 start-page: 1218 year: 2001 ident: 185_CR27 publication-title: BMJ doi: 10.1136/bmj.323.7323.1218 – volume: 40 start-page: 406 year: 2015 ident: 185_CR41 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-015-1263-x – volume: 28 start-page: 2803 year: 2007 ident: 185_CR8 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm358 – volume: 8 start-page: 237 year: 2013 ident: 185_CR56 publication-title: Intern Emerg Med doi: 10.1007/s11739-012-0844-3 – volume: 361 start-page: 1139 year: 2009 ident: 185_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa0905561 – volume: 365 start-page: 883 year: 2011 ident: 185_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1009638 – volume: 320 start-page: 1380 year: 2000 ident: 185_CR36 publication-title: BMJ doi: 10.1136/bmj.320.7246.1380 – volume: 12 start-page: A339 year: 2009 ident: 185_CR46 publication-title: Value Health doi: 10.1016/S1098-3015(10)74667-2 – volume: 28 start-page: 669 year: 2012 ident: 185_CR54 publication-title: Curr Med Res Opin doi: 10.1185/03007995.2012.677419 – volume: 27 start-page: 99 year: 2015 ident: 185_CR17 publication-title: Aging Clin Exp Res doi: 10.1007/s40520-014-0243-x – volume: 32 start-page: 747 year: 2016 ident: 185_CR42 publication-title: Can J Cardiol doi: 10.1016/j.cjca.2015.09.023 – volume: 141 start-page: e1S year: 2012 ident: 185_CR52 publication-title: Chest doi: 10.1378/chest.11-2290 – volume: 37 start-page: 371 year: 2001 ident: 185_CR2 publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(00)01107-4 – ident: 185_CR22 – volume: 18 start-page: A9 year: 2015 ident: 185_CR33 publication-title: Value Health doi: 10.1016/j.jval.2015.03.064 – volume: 21 start-page: 1085 year: 2005 ident: 185_CR38 publication-title: Curr Med Res Opin doi: 10.1185/030079905X50624 – volume: 40 start-page: 268 year: 2015 ident: 185_CR49 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-015-1191-9 – volume: 13 start-page: 108 year: 2013 ident: 185_CR19 publication-title: BMC Cardiovasc Disord doi: 10.1186/1471-2261-13-108 – volume: 111 start-page: 465 year: 2014 ident: 185_CR39 publication-title: Thromb Haemost doi: 10.1160/TH13-05-0424 – volume: 137 start-page: 263 year: 2010 ident: 185_CR13 publication-title: Chest doi: 10.1378/chest.09-1584 – volume: 25 start-page: 548 year: 2005 ident: 185_CR53 publication-title: Med Decis Mak doi: 10.1177/0272989X05280558 – volume: 348 start-page: g3655 year: 2014 ident: 185_CR21 publication-title: BMJ doi: 10.1136/bmj.g3655 – volume: 16 start-page: A11 year: 2013 ident: 185_CR32 publication-title: Value Health doi: 10.1016/j.jval.2013.03.069 – volume: 16 start-page: 262 year: 1996 ident: 185_CR55 publication-title: Med Decis Mak doi: 10.1177/0272989X9601600311 |
| SSID | ssj0061666 |
| Score | 2.374262 |
| SecondaryResourceType | review_article |
| Snippet | Objectives
Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become... Since the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become available for... OBJECTIVESSince the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs), an additional treatment option, apart from VKAs, has become... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 17 |
| SubjectTerms | Administration, Oral Adult Aged Aged, 80 and over Anticoagulants Anticoagulants - therapeutic use Atrial Fibrillation - drug therapy Cardiac arrhythmia Clinical decision making Clinical practice guidelines Decision making Drug therapy Evidence-based medicine Female Health Administration Health Economics Humans Male Medicine Medicine & Public Health Middle Aged Patient Preference - psychology Patients Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Risk Assessment Risk Factors Stroke Stroke - prevention & control Systematic Review |
| SummonAdditionalLinks | – databaseName: Proquest Health and Medical Complete dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BQYgLb2igICNxAlnk4ceaC1ohVhxKWYmC9hYldgwrqmy7u-X3MxM7hqWiFw452U5izdiez2N_H8CL1qBlu8Lx3BaSC1-VvMFAgvtJ7nwlhAj7HV8P9dHRZLEw87jhtonHKsc5cZio3crSHvlrAgoS1zpl3p6ecVKNouxqlNC4CtdINpv8XC8S4FKUEgviKoiUlKzGrCZdnUPcpAlIE56eSG5216ULwebFM5N_JU6H9Wh2-397cgduxUiUTYPr3IUrXX8PbnyMufb78GMeKFfZPEmRbBiGuOzTmpr12GzVfIvqX-w4sBOwZc-mgxIIm9FlgpNQ_IZN2efEGc0OE5czC7mJB_Bl9v743QcepRm4lZXacmsFhg6V8K1tCycQBSFymrTatmhzUzpvG-W975Syrui0kM5I55pSdY33upTVQ9jrV323Dwwrtlr6JhdFJ1RlTVE6fIzxXjmZlxnko2FqG3nLST7jpE6My4MtazqrRrasTQYvU5PTQNpxWeWD0Ux1HL-b-reNMnieinHkUTql6bvVOdZBZKZL7HuVwaPgHOlriPUxdNQqA73jNqkCsXrvlvTL7wO7N-WZ8b0ZvBod7I_f-lcnHl_eiSdws6RwZDhtfgB72_V59xSu25_b5Wb9bBg0vwDamR5B priority: 102 providerName: ProQuest |
| Title | Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review |
| URI | https://link.springer.com/article/10.1007/s40271-016-0185-9 https://www.ncbi.nlm.nih.gov/pubmed/27461276 https://www.proquest.com/docview/1924517569 https://www.proquest.com/docview/1826724603 https://pubmed.ncbi.nlm.nih.gov/PMC5250672 |
| Volume | 10 |
| WOSCitedRecordID | wos000392646500002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1178-1661 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: M0R dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1178-1661 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Proquest Health and Medical Complete customDbUrl: eissn: 1178-1661 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 7X7 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1178-1661 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 7RV dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1178-1661 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: 8C1 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1178-1661 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0061666 issn: 1178-1653 databaseCode: RSV dateStart: 20080101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFD6s7RiFsUt389oVDfa0YfBFF2tvaWnYQ5uFtAt5M7YuXVhxSpLu9-_IssXSroPtwQKjY1l3nU9H-g7Ah1piy5pUx4lKWUxtnsUVKhKxLRJtc0qp3--YnorRqJjN5Li7x73qT7v3Jsl2pg6X3RDpCAd9HQIuWCy3YAdXu8L5a5icT_vplzs7mPeogvCIs7w3Zf4pic3F6I6Gefeg5C1rabsIDZ_-V_afwZNO5yQD30mewwPT7MGjs86qvgeP_d4d8VeSXsCPsSdbJePghGRFULklX5cumQaTWVSXnd8vcuF5Cci8IYPWBwgZumsEVz76MxmQ88AWTU4DizPxVomX8G14cnH8Je6cMsSK5XwdK0VRaciprVWdaor4BzFTUQtVY2vLTFtVcWut4Vzp1AjKtGRaVxk3lbUiY_kr2G4WjXkDBAVrwWyV0NRQniuZZhofKa3lmiVZBEnfOqXqGMud44yrMnAtt5VaulNqrlJLGcHH8Mm1p-v4m_BB3-RlN3JXpQOkDHUqjtHvQzSOOWdIqRqzuEEZxGQiw7LnEbz2PST8DVE-Ko2CRyA2-k4QcHzemzHN_HvL6-0szJhuBJ_6HvRbtu4rxNt_kt6H3czpJe2x8wPYXi9vzDt4qH6u56vlIWyJydSFM9GGBYbFcXoIO0cno_EE384SF-Jw-wXhzB7C |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB5VBQEX3o9AASPBBRSROI4dIyG0KqxadbusxIJ6C4kfsKLKlt0tiD_Fb2QmL1gqeuuBQ062N_Hm83gmM_4-gMelxjfrYhtGJk5D4RMeFuhIhD6LrE-EEM33jg8jNR5nBwd6sgE_u7MwVFbZ2cTaUNu5oW_kzylQSHGvk_rV0deQVKMou9pJaDSw2HM_vmPItny5-xrf7xPOh2-m2zthqyoQmjSRq9AYgbteInxpytgKdODR6c9KZUp8XM2tN4X03jspjY2dEqnVqbUFl67wXnFSiUCTf46Y7GhFZdt9SYmkFFwj5oKRmUyTLotKR_UwTlMUuFP8nqWhXt8HTzi3J2s0_0rU1vvf8Mr_9s9dhcutp80GzdK4Bhuuug4X9ttaghvwZdJQyrJJL7WyZOjCs7cLGlbhsHnxqVU3Y9OGfYHNKjaolU7YkA5LHDbNL9iAves5sdmo56pmTe7lJrw_k6negs1qXrk7wLBjqVJfRCJ2QiZGx9zipbX30qYRDyDqgJCblped5EEO855RusZOTrV4hJ1cB_C0H3LUkJKc1nmrg0Xe2qdl_hsTATzqm9GyULqoqNz8GPtg5KkQ5FESwO0GjP3duBLoGisZgFqDad-BWMvXW6rZ55q9nPLo-LsBPOsA_cdj_WsSd0-fxEO4uDPdH-Wj3fHePbjEyfWqK-u3YHO1OHb34bz5tpotFw_qBcvg41nj_Bf0x34p |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VBVVcKOXpUsoiwQVk1V6vd2MkhCJKRNU0RFBQb669D4ionJKkIP4av44Zr20IFb31wCGn3U288ed5eGa_D-BxmeGdtbEJIx2noXAJDwsMJELXi4xLhBD-fcfHoRqNekdH2XgFfrZnYaitsrWJtaE2U03vyHcoUUjR18lsxzVtEePdwcvTryEpSFGltZXT8BDZtz--Y_o2f7G3i_f6CeeD14ev3oSNwkCo00QuQq0FesBEuFKXsREYzGMC0CuVLvHSM26cLqRzzkqpTWyVSE2WGlNwaQvnFCfFCDT_V3CAE2__QfSu9QKSynFe2AWzNJkmbUWVju1hzqYoiadcvpeG2bJPPBfonu_X_KtoW_vCwfr__C_egOtNBM76_pHZgBVb3YS1g6bH4BZ8GXuqWTbuJFjmDEN79nZGyypcNi0-Napn7NCzMrBJxfq1Agob0CGKEz_8nPXZ-44rmw07DmvmazK34cOlbPUOrFbTyt4DhhNLlboiErEVMtFZzA1-ssw5adKIBxC1oMh1w9dOsiEnecc0XeMopx49wlGeBfC0W3LqyUoumrzVQiRv7NY8_42PAB51w2hxqIxUVHZ6hnMwI1Uc954EcNcDs_s1rgSGzEoGoJYg200gNvPlkWryuWY1p_o6fm8Az1pw_3FZ_9rE5sWbeAhrCO98uDfavw_XOEVkdcP9FqwuZmf2AVzV3xaT-Wy7fnYZHF82zH8B1GOHMA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Patient+Preferences+for+Oral+Anticoagulation+Therapy+in+Atrial+Fibrillation%3A+A+Systematic+Literature+Review&rft.jtitle=The+patient+%3A+patient-centered+outcomes+research&rft.au=Wilke%2C+Thomas&rft.au=Bauer%2C+Sabine&rft.au=Mueller%2C+Sabrina&rft.au=Kohlmann%2C+Thomas&rft.date=2017-02-01&rft.eissn=1178-1661&rft.volume=10&rft.issue=1&rft.spage=17&rft_id=info:doi/10.1007%2Fs40271-016-0185-9&rft_id=info%3Apmid%2F27461276&rft.externalDocID=27461276 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-1653&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-1653&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-1653&client=summon |